RETaliation-Tackling Rare Resistance Alterations to Osimertinib.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37314773.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0993.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
RET fusions occur as a rare mechanism of acquired resistance to osimertinib in patients with EGFR mutation-positive non-small cell lung cancer. Inhibiting RET alongside osimertinib shows promising clinical activity, but innovative approaches are needed to seek regulatory approvals in these rare treatment resistance settings. See related article by Rotow et al., p. 2979.
Medical subject headings
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung